A citation-based method for searching scientific literature

D A Stoffers, T J Kieffer, M A Hussain, D J Drucker, S Bonner-Weir, J F Habener, J M Egan. Diabetes 2000
Times Cited: 454







List of co-cited articles
1114 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
George Grunberger, Sarah Camp, Jeremy Johnson, Susan Huyck, Steven G Terra, James P Mancuso, Zhi Wei Jiang, Gregory Golm, Samuel S Engel, Brett Lauring. Diabetes Ther 2018
68
1

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
351
1

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Paola Fioretto, Stefano Del Prato, John B Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C David Sjöström, Peter Sartipy. Diabetes Obes Metab 2018
62
1

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.
Eduardo De Pablo-Fernandez, Raph Goldacre, Julia Pakpoor, Alastair J Noyce, Thomas T Warner. Neurology 2018
89
1

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
B Wang, J Zhong, H Lin, Z Zhao, Z Yan, H He, Y Ni, D Liu, Z Zhu. Diabetes Obes Metab 2013
129
1



Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
Bo Ahrén, Aniceto Leguizamo Dimas, Patrick Miossec, Stéphane Saubadu, Ronnie Aronson. Diabetes Care 2013
123
1


Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.
Ivana Vrhovac, Daniela Balen Eror, Dirk Klessen, Christa Burger, Davorka Breljak, Ognjen Kraus, Nikola Radović, Stipe Jadrijević, Ivan Aleksic, Thorsten Walles,[...]. Pflugers Arch 2015
145
1


Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.
Olof Eriksson, Torsten Haack, Youssef Hijazi, Lenore Teichert, Veronique Tavernier, Iina Laitinen, Jan Erik Berglund, Gunnar Antoni, Irina Velikyan, Lars Johansson,[...]. Sci Rep 2020
10
10

Canagliflozin: metabolic, cardiovascular and renal protection.
Vivencio Barrios, Carlos Escobar. Future Cardiol 2021
2
50

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Volker Vallon, Maria Gerasimova, Michael A Rose, Takahiro Masuda, Joseph Satriano, Eric Mayoux, Hermann Koepsell, Scott C Thomson, Timo Rieg. Am J Physiol Renal Physiol 2014
258
1

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
Marcel H A Muskiet, Lennart Tonneijck, Yao Huang, Minzhi Liu, Aramesh Saremi, Hiddo J L Heerspink, Daniël H van Raalte. Lancet Diabetes Endocrinol 2018
83
1

Effect of GLP-1 based therapies on diabetic dyslipidemia.
Vishal J Patel, Amit A Joharapurkar, Gaurang B Shah, Mukul R Jain. Curr Diabetes Rev 2014
19
5

Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.
Estela Lajthia, John D Bucheit, Pramit A Nadpara, Dave L Dixon, Lauren M Caldas, Michael Murchie, Evan M Sisson. Pharm Pract (Granada) 2019
5
20

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D Hall, Ele Ferrannini. Diabetes Care 2015
180
1

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
629
1

Sodium Glucose Co-Transporter 2 Inhibitor Ameliorates Autophagic Flux Impairment on Renal Proximal Tubular Cells in Obesity Mice.
Kazuhiko Fukushima, Shinji Kitamura, Kenji Tsuji, Yizhen Sang, Jun Wada. Int J Mol Sci 2020
6
16

GLP-1 Agonists and Blood Pressure: A Review of the Evidence.
Aditya Goud, Jixin Zhong, Matthew Peters, Robert D Brook, Sanjay Rajagopalan. Curr Hypertens Rep 2016
38
2


Exenatide-induced chronic damage of pancreatic tissue in rats.
Xiao Yu, Huayong Tang, Lihua Huang, Yongchao Yang, Buning Tian, Can Yu. Pancreas 2012
16
6

Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.
Juan P Frías, Samer Nakhle, James A Ruggles, Sergey Zhuplatov, Eric Klein, Rong Zhou, Poul Strange. Diabetes Obes Metab 2017
19
5

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Petter Bjornstad, Mark H H Kramer, Michaela Diamant, Ewout J Hoorn, Jaap A Joles, Daniël H van Raalte. Diabetes Obes Metab 2018
12
8



Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
Matthew R Weir, Andrzej Januszewicz, Richard E Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung, Gary Meininger. J Clin Hypertens (Greenwich) 2014
67
1


Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study.
Louisa Sukkar, Amy Kang, Carinna Hockham, Tamara Young, Min Jun, Celine Foote, Roberto Pecoits-Filho, Brendon Neuen, Kris Rogers, Carol Pollock,[...]. Diabetes Care 2020
2
50



Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design.
Shaherin Basith, Minghua Cui, Stephani J Y Macalino, Jongmi Park, Nina A B Clavio, Soosung Kang, Sun Choi. Front Pharmacol 2018
30
3

Acid Loading Unmasks Glucose Homeostatic Instability in Proximal-Tubule-Targeted Insulin/Insulin-Like-Growth-Factor-1 Receptor Dual Knockout Mice.
Abdullah Aljaylani, Maurice Fluitt, Alexandra Piselli, Blythe D Shepard, Swasti Tiwari, Carolyn M Ecelbarger. Cell Physiol Biochem 2020
2
50

Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences.
Ivan Sabolic, Ivana Vrhovac, Daniela Balen Eror, Maria Gerasimova, Michael Rose, Davorka Breljak, Marija Ljubojevic, Hrvoje Brzica, Anne Sebastiani, Serge C Thal,[...]. Am J Physiol Cell Physiol 2012
104
1

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Cristian Guja, Juan P Frías, Aniko Somogyi, Serge Jabbour, Hui Wang, Elise Hardy, Julio Rosenstock. Diabetes Obes Metab 2018
23
4

Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
Michael A Nauck, Juris J Meier. Nat Rev Endocrinol 2011
21
4

Glucose handling by the kidney.
Amanda Mather, Carol Pollock. Kidney Int Suppl 2011
194
1

Development of SGLT1 and SGLT2 inhibitors.
Timo Rieg, Volker Vallon. Diabetologia 2018
85
1

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.
Antonios Douros, Kristian B Filion, Hui Yin, Oriana Hoi Yu, Mahyar Etminan, Jacob A Udell, Laurent Azoulay. Diabetes Care 2018
11
9


Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
K Melissa Hallow, Peter J Greasley, Gabriel Helmlinger, Lulu Chu, Hiddo J Heerspink, David W Boulton. Am J Physiol Renal Physiol 2018
24
4



Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
Hiddo J L Heerspink, Paul Perco, Skander Mulder, Johannes Leierer, Michael K Hansen, Andreas Heinzel, Gert Mayer. Diabetologia 2019
97
1

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
Jessica E Potts, Laura J Gray, Emer M Brady, Kamlesh Khunti, Melanie J Davies, Danielle H Bodicoat. PLoS One 2015
96
1

The impact of antihypertensives on kidney disease.
Diego F Marquez, Gema Ruiz-Hurtado, Luis Ruilope. F1000Res 2017
2
50


Link between Metabolic Syndrome and Insulin Resistance.
Zoran Gluvic, Bozidarka Zaric, Ivana Resanovic, Milan Obradovic, Aleksandar Mitrovic, Djordje Radak, Esma R Isenovic. Curr Vasc Pharmacol 2017
56
1

Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design.
Chelsea K Longwell, Stephanie Hanna, Nina Hartrampf, R Andres Parra Sperberg, Po-Ssu Huang, Bradley L Pentelute, Jennifer R Cochran. ACS Chem Biol 2021
1
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.